CCA
TEVA icon

Catalyst Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Catalyst Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Sell
7,725
-33,175
-81% -$1.1M ﹤0.01% 189
2026
Q1 		$1.23M Buy
+40,900
New +$1.32M 0.02% 131
2025
Q1 		– Sell
-107,250
Closed -$2.36M – 540
2024
Q4 		$2.36M Sell
107,250
-4,800
-4% -$87.3K 0.05% 103
2024
Q3 		$2.02M Buy
+112,050
New +$1.96M 0.05% 114

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Catalyst Capital Advisors's TEVA Position: Q2 2026 in Review

Catalyst Capital Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 81% in Q2 2026, selling an estimated $1.1M and leaving 7,725 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #189.

Catalyst Capital Advisors first reported a position in TEVA in Q3 2024 and has held it in 4 quarters since. The position peaked at $2.36M in Q4 2024. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Catalyst Capital Advisors held 7,725 shares of Teva Pharmaceuticals worth $262K as of Q2 2026.
  • Catalyst Capital Advisors sold 33,175 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.1M.
  • Teva Pharmaceuticals made up ﹤0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #189 holding.
  • Catalyst Capital Advisors first reported a position in Teva Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Catalyst Capital Advisors's Teva Pharmaceuticals position peaked at $2.36M in Q4 2024.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.